- Home
- LXEH vs BOLT Comparison
LXEH vs BOLT Comparison
Compare LXEH & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- BOLT
- Stock Information
- Founded
- LXEH 2001
- BOLT 2015
- Country
- LXEH China
- BOLT United States
- Employees
- LXEH N/A
- BOLT N/A
- Industry
- LXEH Other Consumer Services
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- BOLT Health Care
- Exchange
- LXEH Nasdaq
- BOLT Nasdaq
- Market Cap
- LXEH 12.5M
- BOLT 11.5M
- IPO Year
- LXEH 2020
- BOLT 2021
- Fundamental
- Price
- LXEH $0.36
- BOLT $4.61
- Analyst Decision
- LXEH
- BOLT Buy
- Analyst Count
- LXEH 0
- BOLT 4
- Target Price
- LXEH N/A
- BOLT $34.00
- AVG Volume (30 Days)
- LXEH 1.6M
- BOLT 36.2K
- Earning Date
- LXEH 12-30-2025
- BOLT 11-12-2025
- Dividend Yield
- LXEH N/A
- BOLT N/A
- EPS Growth
- LXEH N/A
- BOLT N/A
- EPS
- LXEH N/A
- BOLT N/A
- Revenue
- LXEH $4,585,942.00
- BOLT $5,195,000.00
- Revenue This Year
- LXEH N/A
- BOLT N/A
- Revenue Next Year
- LXEH N/A
- BOLT N/A
- P/E Ratio
- LXEH N/A
- BOLT N/A
- Revenue Growth
- LXEH N/A
- BOLT N/A
- 52 Week Low
- LXEH $0.31
- BOLT $4.41
- 52 Week High
- LXEH $50.08
- BOLT $13.00
- Technical
- Relative Strength Index (RSI)
- LXEH 29.55
- BOLT 38.69
- Support Level
- LXEH $0.35
- BOLT $4.41
- Resistance Level
- LXEH $0.40
- BOLT $5.14
- Average True Range (ATR)
- LXEH 0.05
- BOLT 0.32
- MACD
- LXEH 0.06
- BOLT -0.07
- Stochastic Oscillator
- LXEH 7.82
- BOLT 13.83
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.